Background -Leukotrienes are lipid mediators generated from arachidonic acid by the 5-lipoxygenase pathway which may play an important part in the pathophysiology of asthma. Previous studies have demonstrated attenuation of the allergen-induced early and late asthmatic responses by leukotriene receptor antagonists. The effect of the 5-lipoxygenase inhibitor ZD2138, a non-redox lipoxygenase inhibitor which inhibits leukotriene synthesis for 24 hours after single doses of 350 mg, on allergen-induced early and late asthmatic responses has been assessed.
Methods -Eight asthmatic subjects with baseline FEVy > 70% were studied. On screening, all subjects developed an allergen-induced biphasic asthmatic response to grass pollen, cat dander, or house dust mite. ZD2138 (350 mg) or placebo was given on two occasions separated by two weeks in a randomised double blind fashion. Allergen inhalation challenge was performed four hours after dosing and FEVI was measured for eight hours. The inhibitory activity of ZD2138 on the 5-lipoxygenase pathway was assessed by measurements of calcium ionophorestimulated generation of LTB4 in whole blood ex vivo and by analysis of urinary LTE4 levels before administration of drug or placebo and at regular intervals after oral drug dosing and allergen challenge. Results -ZD2138 produced no significant bronchodilatation or attenuation of the early or late asthmatic response, although there was 82% inhibition of whole blood generation of LTB4 in response to calcium ionophore stimulation and 52% reduction in urinary excretion of LTE4.
Conclusions -In asthmatic subjects the 5-lipoxygenase inhibitor ZD2138 did not protect against allergen-induced asthmatic responses, despite substantial inhibition of 5- Delivery of air to the nebuliser was regulated to a pressure of 138 kPa (20 psi) for a duration of 0-6 seconds from the start of each breath. There was no time lag between inspiration and actuation of the dosimeter. Under these conditions the nebuliser delivers droplets with a mass median aerodynamic diameter of 1-6 iim and the output of the nebuliser is 2 6 gl per actuation. After baseline measurements of FEVI the subjects inhaled five breaths of Coca's solution as control. Each dose consisted of five submaximal breaths starting at functional residual capacity followed by a five second breath hold. If the decrease in FEV1 following Coca's solution was < 10% the subjects underwent allergen challenge. Incremental doubling concentrations of allergen diluted in Coca's solution were used for bronchial challenge at 15 minute intervals with FEVI measurements at 5, 10, and 15 minutes until a fall in FEVI of at least 20% was achieved. Further measurements of FEV, were made at 20, 30, and 60 minutes and then hourly until eight hours after allergen challenge. Subsequent allergen challenges on days 2 and 3 were performed using the final three allergen concentrations leading to a 20% fall in FEVI and were given sequentially at 10 minute intervals. The coefficient of repeatability of the early and late asthmatic reactions following allergen challenge in 26 subjects in our laboratory is 38% and 27% respectively.
All eight subjects were given 200 jtg salbutamol routinely at the end of the period of urine collection. No subject required treatment.
MEASUREMENT OF URINARY LTE4
The free radical scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidinooxy free radical (4-hydroxy-TEMPO; Sigma Chemical Company, Poole, Dorset, UK) was added to each urine sample immediately after collection to a final concentration of 1 mmol/l, the samples were adjusted to pH 9 Figure 2 shows the mean ionophore-induced generation of LTB4 from whole blood after placebo and ZD2138. No difference between the two baseline LTB4 levels was found. There was a statistically significant difference between the ZD2138 and placebo days for the area under the curves (p = 0 01), with an 82% reduction in LTB4 generation on the ZD2138 day compared with placebo. Linear regression analysis demonstrated no significant correlation between percentage inhibition of ex vivo generation of whole blood LTB4 and the early (r=0-55; p=015) or late (r= -0 12; p=077) asthmatic response.
URINARY LTE4
There was no significant difference between baseline urinary LTE4 levels on the two days (fig 3) . Comparison of the area under the curves indicated a 52% reduction in urinary LTE4 excretion following ZD2138 compared with that observed after administration of placebo (p=0013). Linear regression analysis demonstrated no correlation between percentage inhibition of urinary LTE4 excretion and either the early (r= 053; p = 0 18) or the late (r -023; p = 0 58) asthmatic response. ZD2138 was well tolerated and no adverse events attributed to the drug occurred in this study. All eight subjects completed the study.
Discussion
There is increasing evidence that leukotrienes may contribute to the inflammation of the airways, hyperresponsivenes of the airways, and the acute bronchospasm that characterise bronchial asthma. In support of this hypothesis leukotrienes have been recovered from the bronchoalveolar lavage fluid of asthmatic subjects at rest'415 and following challenge with allergen '6 17 and isocapnic hyperventilation. In this study we evaluated the effect of a 5-lipoxygenase inhibitor on allergen-induced asthma. ZD2138 was developed from a class of 5-lipoxygenase inhibitors that inhibit the enzyme via an enantioselective mechanism.34 In vitro data on whole blood show that it is the most potent and most selective 5-lipoxygenase inhibitor yet reported,27 and has a half life after absorption of 12 hours. Inhibition of 5-lipoxygenase, which is both maximal (>90%) and sustained for 24 hours, is obtained at a plasma concentration of 80 ng/ml which is achieved with a dose of 350 mg or more. Subjects were fasted in the present study to standardise oral bioavailability. 5-lipoxygenase activity was monitored by measuring whole blood generation of LTB4 in response to calcium ionophore, and by measuring urinary excretion of LTE4 following allergen challenge. Administration of ZD2 138 led to an 86% inhibition in whole blood generation of LTB4 at four hours after dosing immediately before allergen challenge, 85% inhibition of whole blood LTB4 generation 12 hours after dosing during the late asthmatic response, and 83% inhibition at 24 hours after dosing. Administration of ZD2138 led to a significant decrease in urinary excretion of LTE4 before allergen challenge and attenuated the allergen-induced rise in urinary LTE4 excretion which was observed on the placebo day. Despite this evidence for effective inhibition of 5-lipoxygenase activity there was no attenuation of early or late asthmatic responses to allergen following administration of ZD2138. These findings are in agreement with those of Hul et al who found no effect of the 5- 
